Title: Safety experience with caspofungin in pediatric patients
Authors: Zaoutis, Theoklis ×
Lehrnbecher, Thomas
Groll, Andreas H
Steinbach, William J
Jafri, Hasan S
Maertens, Johan
Ngai, Angela L
Chow, Joseph W
Taylor, Arlene F
Strohmaier, Kim M
Bourque, Michael
Bradshaw, Susan K
Petrecz, Maria
Kartsonis, Nicholas A #
Issue Date: Dec-2009
Publisher: Williams & Wilkins
Series Title: The Pediatric Infectious Disease Journal vol:28 issue:12 pages:1132-1135
Abstract: We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.
ISSN: 0891-3668
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Hematology Section (-)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science